Differential Release of Heterogeneous Human Mesenchymal Stem Cell Populations from Haemarthrotic Traumatic Knee Injury

David J. Deehan1,2, Daniel J. Dowen1, Andrew P. Sprowson1, Linda C. Ferguson1, Nilendran S. Prathalingam3, John D. Isaacs1,2, Mark A. Birch1, Rachel A. Oldershaw1,*

1Institute of Cellular Medicine, Faculty of Medical Sciences, Newcastle University, Medical School, Framlington Place, Newcastle-upon-Tyne, NE2 4HH, UK
2Freeman Hospital, Newcastle-Upon-Tyne NHS Trust, Freeman Road, High Heaton, Newcastle-upon-Tyne, NE7 7DN, UK
3Institute of Ageing and Health, Faculty of Medical Sciences, Newcastle University, International Centre for Life, Times Square, Newcastle-upon-Tyne, NE1 4EP, UK

Abstract
Surgical reconstruction of the anterior cruciate ligament (ACL) has a protracted healing phase due to poor osseous tissue integration at the graft/host interface. Intervention with an autologous cell-based therapy using human mesenchymal stem cells (hMSCs) derived from haemarthrotic fluid aspirated at the acute phase of injury has been postulated to accelerate healing, though until now the practicalities of this approach have not been demonstrated. hMSCs were derived by plastic adherence from haemarthrosis fluid aspirated from 20 patients presenting at clinic with acute knee injury. Patient details were recorded including age and sex of patient, injury and time between injury and aspiration. The phenotype of hMSCs was characterised by flow cytometry analysis of cell surface antigens. Differentiation potential was analysed by culturing hMSCs with different pro-differentiation stimuli to drive osteogenesis, adipogenesis and chondrogenesis. Comparative analysis of differentiation was made by quantitative PCR for lineage-specific gene expression and quantitative biochemical analyses. hMSC derivation was independent of age, sex and time between injury and aspiration however there was a statistically significant increase in frequency of derivation from haemarthrosis samples that had been aspirated from bone fracture injuries compared to soft tissue injuries. hMSCs showed differential expression of cell surface antigens and there were also significant differences in their osteogenic, adipogenic and chondrogenic responses between samples. We have demonstrated the feasibility of deriving multipotent hMSCs from haemarthrosis fluid aspirated from acute knee injuries. Further optimisation of processing and differentiation methodologies must be achieved to develop a feasible clinical treatment which accelerates ACL reconstruction. This study has identified challenges in the harvesting, bio-processing and characterisation of hMSCs which would be broadly applicable to the development of all autologous orthopaedic cell therapies.

Keywords
Haemarthrosis, Mesenchymal Stem Cell, Multipotent Differentiation, Acute Knee Trauma

1. Introduction
Injury and rupture of the anterior cruciate ligament (ACL) as a result of trauma is common and results in acute bleeding into the knee joint[1]. The reconstruction of the ligament requires the tethering of an autograft inside a bony tunnel and the successful surgical outcome of this technique is wholly dependent upon tissue integration and remodelling to enable strong anchorage at the graft/host interface[2].

Adult stem cells, particularly human mesenchymal stem cells (hMSCs), have long held significant potential for their application in the reconstruction and regeneration of orthopaedic tissues including cartilage, bone, tendon and meniscus[3-6]. Within the context of ACL reconstruction hMSCs potentially offer a new autologous therapeutic modality to accelerate tissue repair, graft integration and restoration of normal knee function. Whilst commonly being derived from the stromal compartment of bone marrow hMSCs have been sourced from diverse tissues including adipose, trabecular bone, cartilage, skeletal muscle, peripheral blood and synovial fluid[7-10]. Analgesic aspiration of an acute knee effusion could therefore allow for harvesting of blood and tissue fluid with a view to isolating hMSCs[11, 12]. This presents a practicable clinical model by which hMSCs are derived, expanded and assembled into an autologous deliverable product during the 10-12 week period required for stabilisation of the knee joint prior to reconstructive surgery.

We wished to examine the feasibility of reproducibly
harvesting and isolating hMSCs from haemarthroses and demonstrate their multipotential with the longer term view of their introduction with a scaffold to enhance tissue repair. We have investigated the derivation of hMSCs from a consecutive series of 20 patients who presented at clinic with a diverse range of acute knee trauma. hMSC populations were characterised for expression of key cell surface antigens and the potential to undergo *in vitro* differentiation to chondrocytes, osteoblasts and adipocytes. We report our experience and outline the early difficulties encountered in advancing this therapeutic approach.

## 2. Materials and Methods

### 2.1. Acquisition of haemarthrosis fluid

All patients gave informed consent according to Ethical Committee guidelines. A consecutive series of patients presenting with a traumatic knee haemarthrosis underwent aspiration under aseptic conditions. Samples were collected in heparinised specimen tubes and immediately stored at 4ºC. Samples were processed within 24 hours of aspiration. Clinical diagnoses as suspected through clinical examination were confirmed by plain radiography and MRI scanning.

### 2.2. Cell Culture

All cell culture reagents were purchased from Invitrogen, Paisley, UK unless otherwise stated.

#### 2.2.1. Derivation and culture of hMSC

Hemarthrosis fluid was diluted with DPBS at a ratio of 1:4, layered onto a 12ml volume of Ficoll-Paque™ Premium (GE Healthcare Life Sciences, Buckinghamshire, UK) and centrifuged at 600 x g for 20 minutes. The mononuclear cell fraction was centrifuged at 25,000 x g for 5 minutes and the cell pellet resuspended in hMSC medium (Minimum Essential Medium (MEM) α medium, 10% (vol/vol) FBS, 2mM GlutaMAX™, 5ng/ml FGF2) and seeded in a T-75 cell culture flask at a density of 300 x 10^5 cells / cm². After 24 hours culture medium was removed and the culture area rinsed with DPBS. Bone marrow mononuclear cells (Lonza, Wokingham, UK) were seeded in a T-75 cell culture flask at a density of 300 x 10^5 cells / cm² and cultured in hMSC medium as previously described[13].

#### 2.2.2. Osteogenic differentiation

hMSCs were seeded cultured with osteogenic medium (Dulbecco’s Modified Eagles Medium (DMEM), 10% (vol/vol) FBS, 2mM GlutaMAX™, 10mM β-glycerophosphate, 10mM dexamethasone, 100mM L-ascorbic acid-2-phosphate). Cultures were maintained for 4 weeks[14].

#### 2.2.3. Chondrogenic differentiation

hMSC were detached from monolayer and resuspended in chondrogenic medium (Dulbecco’s Modified Eagles Medium (DMEM), 2mM GlutaMAX™, 100nM dexamethasone, 100nM L-ascorbic acid-2-phosphate, 40µg/ml L-proline, 1% (vol/vol) ITS+1, 10ng/ml TGF-β3). Cell aggregates (5 x 10^5 cells / aggregate) were formed by centrifuging the tubes at 300 x g for 5 minutes. Cultures were maintained for 2 weeks[13].

### 2.2.4. Adipogenic Differentiation

Adipogenic differentiation was initiated by cyclical treatment of 72 hours culture with adipogenic induction medium (Dulbecco’s Modified Eagles Medium (DMEM), 10% (vol/vol) FBS, 2mM GlutaMAX™, 1% (vol/vol) ITS+1, 1µM dexamethasone, 100µM indomethacin, 500µM 3-isobuty-1-methylxanthine) followed by 24 hours culture with adipogenic maintenance medium (Dulbecco’s Modified Eagles Medium (DMEM), 10% (vol/vol) FBS, 2mM GlutaMAX™, 1% (vol/vol) ITS+1). After 4 cycles cells were cultured for 7 days in adipogenic maintenance medium[14].

### 2.3. Flow Cytometry

hMSC populations were analysed by flow cytometry[15]; primary antibodies(5µg/ml) were taken from the Human Multipotent Mesenchymal Stromal Cell Marker Antibody Panel (R&D Systems, Minneapolis, USA), secondary antibody (donkey anti-mouse IgG Alexa 488; 8µg/ml (Molecular Probes, Invitrogen)). Cell labelling was analysed with a BD FACScanto™ II flow cytometer and BD FACSDiva™ software (BD, Oxford, UK).

### 2.4. Gene Expression Analysis

Total RNA was prepared from monolayer cell cultures using Tri-reagent. Total RNA was prepared from chondrogenic cell aggregates using Tri-reagent in conjunction with the Molecular Grinding Resin™ with Pestle and Mortar kit (GBiosciences, St Louis, USA). Total RNA(1µg per reaction) was reverse transcribed using 500ng random hexamers, 500µM dNTPs, 200U M-MLV reverse transcriptase and 1 X reverse transcription reaction buffer (Promega, Southampton, UK). Quantitative PCR(qPCR) was performed with the qPCR™ Core Kit for Sybr™ Green I. Each qPCR reaction was assembled to a total volume of 25µl using 1µl cDNA template, 300nM gene-specific forward and reverse primer set, 1 X PCR reaction buffer, 3.5mM MgCl2, 200µM dNTPs, 0.625U HotGoldStar enzyme, 1:6600 Sybr Green I. Gene-specific forward and reverse primer sets were as previously published; GAPDH[16], AP2 and LIPOPROTEIN LIPOASE[17], CBFA1 and ALKALINE PHOSPHATASE[18]. Data was normalised to GAPDH using the delta-delta method[19].

### 2.5. Histological Analysis

#### 2.5.1. Safranin O stain of chondrogenic cell aggregates

Chondrogenic cell aggregates were fixed in 4% (vol/vol) formaldehyde, embedded in paraffin wax and sectioned (5µm). Deparaffinised sections were stained in Harris'
haematoxylin, stained with 0.02% (wt/vol) aqueous fast green FCF for 3 minutes, and stained with 0.1% (wt/vol) aqueous safranin O for 5 minutes. Slides were mounted using DePeX mounting medium.

2.5.2. Alizarin red stain of osteogenic cultures

Osteogenic cultures were stained with Alizarin Red (2% wt/vol, pH4.2) for 2 hours at room temperature. Quantification of alizarin red staining was carried out by solubilising cell cultures with 2% (wt/vol) SDS and measuring the absorbance (A492) using a Multiskan Ascent plate reader (MTX Lab Systems, Inc., Vienna, USA).

2.6. Biochemical Analysis

2.6.1. Preparation of Cell Lysates

Monolayer cell cultures were lysed in 2ml volumes of 0.01% Triton-X-100. Chondrogenic cell aggregates were digested in 20µl of 10U/ml of papain in papain buffer (100mM sodium acetate, 2.4mM EDTA, 5mM L-cysteine (pH5.8)) at 60°C.

2.6.2. Quantification of DNA

Total DNA in the prepared cell lysates was measured using the Quant-it™ PicoGreen® dsDNA Assay kit. Fluorescence was measured using a Fluoroskan I plate reader (MTX Lab Systems, Inc.).

2.6.3. Metachromatic Quantification of Sulphated Glycosaminoglycans

Quantification of sGAG was carried out by 1,9-dimethylmethylen blue (DMMB) assay. Experimental samples were mixed with DMMB solution (0.16% (wt/vol) DMMB, 0.2% (vol/vol) formic acid, 30mM sodium formate (pH 3.5)) and the absorbance (A955) read using a Multiskan Ascent plate reader (MTX Lab Systems, Inc.). Values were calibrated against known concentrations of shark chondroitin sulphate.

2.7. Statistical Analysis

Two-sample Student’s T-tests were carried out on data sets that were seen to be normally distributed. Where data was not normally distributed non-parametric equivalents were used.

3. Results

3.1. Derivation of hMSC Populations from Haemarthrosis Fluid

We compared the ability to derive hMSC populations from haemarthrosis fluid that had been aspirated from 20 consecutive patients presenting at clinic with a diverse range of acute knee trauma (Table 1). The study group comprised 11 male and 9 female patients aged between 15-79 years with the average age being 48 years and the median age 52 years. Eight of the twenty acute knee injuries were resultant of soft tissue ruptures where bleeding into the synovial joint space would occur solely from the peripheral circulation. Bone fractures accounted for twelve of the twenty acute knee injuries and as such the aspirated haemarthrosis would contain a further molecular and cellular contribution from the bone marrow compartment of the osseous tissue. For the majority of samples aspiration of the haemarthrosis took place within 1 day of injury. Five of the samples were aspirated within 1 week and the remaining around 2 weeks (sample 3, 15 days; sample 14, 14 days) post-injury.

We observed a significant amount of haemolysis within some of the samples such that we were frequently unable to resolve clear phase separation of the mononuclear cell fractions following ficoll-gradient centrifugation. Colony-forming unit fibroblasts (CFU-Fs) with characteristic hMSC morphology were observed between 7-14 days post-seeding from twelve out of twenty samples. The number of CFU-Fs obtained from each sample was independent of the amount of fluid that was aspirated. The ability to derive hMSC populations was independent of gender, age and time between injury and aspiration; however there was a significant difference between rate of derivation and the origin of haemarthrosis. We derived hMSC populations from 9 out of the 12 samples that had been aspirated following bone fracture injuries compared to three of the eight haemarthroses arising from soft tissue ruptures (P<0.005).

3.2. Human Mesenchymal Stem Cell Populations Derived from Aspirated Haemarthroses Display Heterogeneous Cell Surface Antigen Expression between Samples

Populations of hMSCs that had been successfully derived from aspirated haemarthroses were expanded to passage 2 in vitro culture and analysed by flow cytometry for the expression of characteristic hMSC morphology were observed between 7-14 days post-seeding from twelve out of twenty samples. The number of CFU-Fs obtained from each sample was independent of the amount of fluid that was aspirated. The ability to derive hMSC populations was independent of gender, age and time between injury and aspiration; however there was a significant difference between rate of derivation and the origin of haemarthrosis. We derived hMSC populations from 9 out of the 12 samples that had been aspirated following bone fracture injuries compared to three of the eight haemarthroses arising from soft tissue ruptures (P<0.005).

The proportion of hMSCs expressing each of the cell surface antigens was highly heterogeneous between samples. In general, a high proportion of each cell population was seen to express CD44, CD90, CD105 and CD166. CD44 was expressed on over 94% of hMSC populations with the exception of samples 3, 1 and 17. CD90 was expressed on over 95% of hMSC populations with the exception of samples 3, 1 and 17. CD90 was expressed on over 95% of hMSC populations with the exception of samples 6, 3 and 18. CD105 was expressed on over 95% of hMSC population with the exception of samples 11, 3, 17 and 6. The cell surface antigen CD166 was expressed on a relatively high proportion of cells (>80%) within hMSC populations derived from samples 1, 11, 17, 18 and 20. The proportion of cells expressing the cell surface antigens
Table 1. Characterisation of haemarthrosis fluid samples aspirated from 20 patients presenting at clinic with acute knee trauma. The ability to derive hMSC populations from each haemarthrosis is shown. Alongside we have presented the age and gender of the patient and the clinical diagnosis of the acute knee injury. The injuries are classified for the origin of the haemarthrosis and the time between injury and aspiration for each sample.

<table>
<thead>
<tr>
<th>SAMPLE</th>
<th>AGE</th>
<th>GENDER</th>
<th>INJURY</th>
<th>ORIGIN OF HAEMARTHROSIS (Bone Marrow or Soft Tissue)</th>
<th>TIME BETWEEN INJURY AND ASPIRATION</th>
<th>MSC DERIVED</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>15</td>
<td>Male</td>
<td>Patella</td>
<td>Bone Marrow</td>
<td>1 week</td>
<td>YES</td>
</tr>
<tr>
<td>2</td>
<td>54</td>
<td>Female</td>
<td>Tib plateau</td>
<td>Bone Marrow</td>
<td>4 days</td>
<td>YES</td>
</tr>
<tr>
<td>3</td>
<td>55</td>
<td>Male</td>
<td>Tib plate + shaft</td>
<td>Bone Marrow</td>
<td>15 days</td>
<td>YES</td>
</tr>
<tr>
<td>4</td>
<td>73</td>
<td>Female</td>
<td>Tib plateau</td>
<td>Bone Marrow</td>
<td>1 day</td>
<td>NO</td>
</tr>
<tr>
<td>5</td>
<td>30</td>
<td>Female</td>
<td>Patella dislocation</td>
<td>Soft Tissue</td>
<td>1 day</td>
<td>NO</td>
</tr>
<tr>
<td>6</td>
<td>59</td>
<td>Female</td>
<td>Patella dislocation</td>
<td>Soft Tissue</td>
<td>1 day</td>
<td>YES</td>
</tr>
<tr>
<td>7</td>
<td>79</td>
<td>Male</td>
<td>Patella</td>
<td>Bone Marrow</td>
<td>1 day</td>
<td>NO</td>
</tr>
<tr>
<td>8</td>
<td>44</td>
<td>Female</td>
<td>MCL + ACL</td>
<td>Soft Tissue</td>
<td>3 days</td>
<td>YES</td>
</tr>
<tr>
<td>9</td>
<td>20</td>
<td>Male</td>
<td>Patella dislocation</td>
<td>Soft Tissue</td>
<td>1 day</td>
<td>NO</td>
</tr>
<tr>
<td>10</td>
<td>63</td>
<td>Female</td>
<td>Tib plateau</td>
<td>Bone Marrow</td>
<td>1 day</td>
<td>NO</td>
</tr>
<tr>
<td>11</td>
<td>49</td>
<td>Female</td>
<td>Tib plate + shaft</td>
<td>Bone Marrow</td>
<td>1 day</td>
<td>YES</td>
</tr>
<tr>
<td>12</td>
<td>47</td>
<td>Male</td>
<td>Tib Plate</td>
<td>Bone Marrow</td>
<td>1 day</td>
<td>YES</td>
</tr>
<tr>
<td>13</td>
<td>66</td>
<td>Female</td>
<td>PCL Avulsion</td>
<td>Bone Marrow</td>
<td>1 day</td>
<td>YES</td>
</tr>
<tr>
<td>14</td>
<td>47</td>
<td>Female</td>
<td>Med rotinacular inj</td>
<td>Soft Tissue</td>
<td>2 weeks</td>
<td>YES</td>
</tr>
<tr>
<td>15</td>
<td>18</td>
<td>Male</td>
<td>ACL rupture</td>
<td>Soft Tissue</td>
<td>2 days</td>
<td>NO</td>
</tr>
<tr>
<td>16</td>
<td>43</td>
<td>Male</td>
<td>Tib spine avulsion</td>
<td>Bone Marrow</td>
<td>4 days</td>
<td>YES</td>
</tr>
<tr>
<td>17</td>
<td>20</td>
<td>Male</td>
<td>Patella</td>
<td>Bone Marrow</td>
<td>1 day</td>
<td>YES</td>
</tr>
<tr>
<td>18</td>
<td>21</td>
<td>Male</td>
<td>ACL rupture</td>
<td>Soft Tissue</td>
<td>1 day</td>
<td>YES</td>
</tr>
<tr>
<td>19</td>
<td>79</td>
<td>Male</td>
<td>Med rotinacular rupture</td>
<td>Bone Marrow</td>
<td>1 day</td>
<td>NO</td>
</tr>
<tr>
<td>20</td>
<td>60</td>
<td>Female</td>
<td>Patella</td>
<td>Bone Marrow</td>
<td>1 day</td>
<td>YES</td>
</tr>
</tbody>
</table>

CD106 and CD146 were lower and also more heterogeneous across cell populations.

In addition to characterising the expression of known hMSC cell surface antigens we carried out flow cytometry analysis for the cell surface antigens CD19 and CD45 (expressed on haematopoietic stem cells and their cell lineage derivatives but not hMSCs). There was no detectable expression of CD19 or CD45 within hMSC populations derived from haemarthrosis samples 6, 11 and 17. There was a small proportion of hMSCs that were shown to express CD19 within samples 1 and 13 and CD45 within samples 16, 18 and 20. Significantly, hMSC populations that were derived from samples 13 and 18 contained high proportions of cells that expressed CD45 and CD19 respectively. Sample 3 was seen to be the most heterogeneous of the hMSC populations with cells expressing both CD19 (66%) and CD45 (50%).

3.3. Human Mesenchymal Stem Cell Populations Derived from Haemarthroses Exhibit Variation in Multipotent Differentiation between Samples

To investigate the potential for multipotent differentiation, hMSC populations that had been successfully derived from haemarthrosis samples were expanded to passage 2 before being cultured in vitro with appropriate stimuli to promote differentiation to osteoblast, adipocyte and chondrocyte cell lineages[11,12].

All twelve of the hMSC populations that had been derived from haemarthrosis samples underwent osteogenic differentiation. At day 0 hMSCs that had been seeded at low cell density were seen to have a characteristic fibroblastic morphology. After 28 days of osteogenic differentiation significant cellular proliferation was evident. Cells had acquired an osteoblast-like cuboidal cell morphology and were encased within an extensive extracellular matrix (data not shown). CBFA1 and ALKALINE PHOSPHATASE, key markers of osteoblast phenotype, were expressed within all osteogenic cultures after 28 days though expression varied between hMSC populations by 100-fold and 1000-fold respectively for each gene(Figure 2a, b). Quantification of the amount of DNA was carried out at day 0 and day 28 as a measure of the amount of cellular proliferation that occurred during osteogenic differentiation(Figure 2c). For the majority of hMSC populations there was between 4 and 6-fold...
increase in DNA during osteogenic differentiation, indicative of cells within the culture having undergone 2-3 rounds of cell division. Some cell populations showed greater proliferative potential with 8 and 12-fold increases in the amount DNA(3-4 rounds of cell division) and 20 to 30-fold increases(5-6 rounds of cell division).

Histological characterisation for calcified matrix was carried out by staining cell cultures with alizarin red (Figure 2d). Unsurprisingly at day 0 alizarin red staining was negative. In contrast, at day 28 there was significant alizarin red staining across the culture dish and this was apparent for all haemarthrosis-derived hMSC cultures that had between treated with pro-osteogenic stimuli. To provide a quantitative measure of matrix calcification, day 28 cultures that had been stained with alizarin red were solubilised and the absorbance read at A492. We have presented this as absorbance per amount of DNA within each sample; reflecting the contribution to matrix calcification per cell (Figure 2e).

Biochemical analysis was carried out to measure the fold change in the amounts of DNA (Figure 4e) and sGAG (Figure 4f) within cell aggregates after 14 days of chondrogenic differentiation. For all but three of the hMSC populations there was on average a one third decline in the amount of DNA measured at days 0 and day 14 and hence a loss of cellular content from the cell aggregates during chondrogenic differentiation. Only one out the twelve samples that were assayed for chondrogenic differentiation(sample 20) showed a significant increase in cellular proliferation (3.2 fold increase between days 0 and 14; P<0.05). The accumulation of sGAG during chondrogenic differentiation of cell aggregates was quantified by DMMB assay (Figure 4f).

In contrast to osteogenic and adipogenic differentiation, the chondrogenic response of haemarthrosis-derived hMSCs was poor and we were unable to extract quantities of RNA required for gene expression analysis. In addition hMSCs derived from sample 18 did not form cell aggregates. Characterisation data of chondrogenic phenotype is therefore presented alongside that of human bone marrow-derived hMSCs as a positive control. Histological evaluation of sGAG, a key component of cartilage matrix, was carried out on cell aggregates which had been cultured for 14 days in pro-chondrogenic medium. Cell aggregates which had been formed from hMSCs derived from bone marrow mononuclear cells stained strongly with safranin O and at higher magnification lacunae-bound chondrocyte-like cells were seen to be encased within an extensive extracellular matrix (Figure 4a-b). In contrast cell aggregates that had been formed from hMSCs derived from haemarthrosis fluid were more heterogeneous in their cellular organisation (Figure 4c). Only a small portion of the tissue stained strongly with safranin O. At higher magnification (Figure 4d) lacunae-bound chondrocyte-like cells were seen but the remaining aggregate tissue had a fibroblastic phenotype which counter-stained with fast green.

All twelve of the hMSC populations that had been derived from haemarthroses samples underwent adipogenic differentiation. AP2 and LIPOPROTEIN LIPASE, key markers of adipogenic phenotype, were expressed within all adipogenic cultures after 30 days though expression varied between hMSC populations by up to 1000-fold for each gene (Figure 3a-b). Cell cultures treated with pro-adipogenic stimuli began to show evidence of lipid vesicle accumulation within cells from cycle 3 of differentiation onwards. The number and size of lipid vesicles within individual cells continued to increase such that by the end of the differentiation period adipogenic cells were clearly visible across 10-20% of the culture area. Adipogenic cells are seen as greatly enlarged cells packed densely with cytoplasmic vesicles (Figure 3c).
significant increase in the amount of sGAG formed from hMSC populations derived from samples 1, 11, 12 and 13. Cell aggregates formed from hMSCs derived from bone marrow showed little increase in cell proliferation during the 14 days of chondrogenic differentiation but there was over 10-fold increase in the amount of sGAG accumulated in comparison to the most robust of cell aggregates derived from haemarthrosis fluid.

Figure 4. Characterisation of chondrogenic differentiation potential of hMSC populations. Chondrogenic differentiation was analysed by safranin O staining of cells aggregate sections. (a) Images at low magnification revealed strong safranin O staining of cell aggregates formed from hMSCs derived from bone marrow; scale bar = 500µm. (b) At higher magnification rounded chondrocyte-like cells were shown to be encased within an extensive ECM; scale bar = 100µm. (c) Safranin O staining of cell aggregates formed from hMSCs derived from haemarthrosis fluid. Staining was weaker in comparison to that observed in cell aggregates formed from hMSCs derived from bone marrow and was also more heterogeneous staining within the cell aggregates; scale bar = 500µm. (d) At high magnification rounded chondrocyte-like cells were shown to be encased within an extensive ECM; scale bar = 100µm. (e) Cellular proliferation during chondrogenic differentiation was recorded as the fold-change in the amount of DNA between cell aggregates cultures at day 0 and day 14. (f) Fold-change in the amount of sGAG accumulated between day 0 and day 14 of chondrogenic culture was measured by DMMB assay. BM = bone marrow. Values represent mean values ± S.E.M; n=3.

4. Discussion

The presence of hMSC populations within synovial fluid is well documented and their elevated numbers in response to disease and trauma demonstrates a role in the repair of damaged tissues within the synovial joint[8, 9, 20-22]. Our aim in this study was to investigate the potential of these cells as an autologous cell-based therapeutic modality. It has been argued that such cells may play a role in accelerating graft integration at time of surgical reconstruction[20-23]. This study accurately defines the potential yield, identifies the limitations in such work and begins to characterise the behaviour of such cells in relation to clinical characteristics. Only until such work is complete can this new technology become clinically and commercially deliverable.

In this study hMSC populations were derived from 60% of haemarthrosis aspirates that were collected from clinic. Derivation of hMSCs was independent of gender, time from injury to aspiration or the nature of the intra-articular event. Previous studies have found that hMSC derivation and culture is dependent on age[24, 25]. However, although we were unable to derive cells from the three most elderly patients, we were able to successfully obtain MSC populations from haemarthrosis fluid which had been aspirated from patients up to 66 years of age.

The greatest influence on the ability to derive hMSCs was the origin of the haemarthrosis. We were significantly more successful at deriving hMSC populations from haemarthroses arising from bone fractures where there would have been an additional cellular component from the bone marrow compartment. From our observations and handling of the haemarthrosis samples, we would consider that the quality of the aspirate also influenced the ability to derive hMSCs. Despite patients being administered with heparin upon presentation at the clinic and also collection of the aspirate into heparin containing collection tubes there was a significant frequency of blood clotting and haemolysis between the aspiration and processing of the sample. This haemolysis appeared to compromise the ability to obtain clear phase separation from Ficoll-gradient centrifugation and resulted in contamination of the mononuclear cell population. We conjecture that this may have been a contributing factor in our inability to derive hMSCs from some haemarthroses and will preclude the derivation of adequate cells for the generation of clinically deliverable product. Further understanding of the bio-processing procedures involved, such as aspiration technique, initial tissue handling and optimisation of the conditions used to store and transport the haemarthrosis fluid should reduce the frequency of haemolysis.

We specifically characterised hMSC populations at passage 2 since we consider this to be the most appropriate point at which the cells would be used clinically. Using hMSCs at low passage should reduce the risk of deleterious effects brought about by adaptation to in vitro culture[26] whilst permitting the amplification of significant cell numbers for generating the clinical deliverable and use in mandatory testing as required by the appropriate regulatory agencies (Eudralex, Volume 4, Annex 2).

Flow cytometry was carried out using a panel of commercially available antibodies specific for cell surface antigens expressed on hMSCs[6]. Differential expression of each antigen demonstrated that we derived highly heterogeneous populations; it is likely that these would become more homogeneous with prolonged culture[27, 28]. Whilst most antigens are expressed within high proportions of each cell population (CD44, CD90, CD105 and CD166) we noted...
much lower and more heterogeneous expression between cell populations when analysing expression of CD106 and CD146. Flow cytometry analysis will be one method by which we would carry out the necessary validation of cultured hMSC populations prior to clinical application. This data suggests that we will need to undertake a more considered approach in identifying a panel of appropriate antigens that will give us reliable characterisation of the hMSC phenotype with the minimum number of cells.

In some samples there were large numbers of cells expressing the non-mesenchymal antigens, CD19 and CD45. It is likely that these cells would be lost during continued culture expansion though having argued strongly for the clinical application of these cells at low passage their exclusion from the final cell therapy must be addressed. We believe reduction of haemolysis will enable the isolation of cleaner mononuclear cell fractions and reduce lymphocyte contamination. It may be possible to introduce a negative selection technique to remove contaminating cells prior to incorporating the hMSCs onto the selected scaffold[29].

Gene expression and biochemical analyses showed that we derived multipotent hMSC cells though there was a varied response to differentiation stimuli between cell populations. All of the twelve hMSC populations derived underwent adipogenic and osteogenic differentiation though some populations had a more robust proliferative and/or differentiation response than others. It is possible that for some samples(for instance sample 3) in which there were contaminating CD19+, CD45+ lymphocyte populations the cells had a more pro-inflammatory phenotype resulting in more proliferation over differentiation. Whilst there was evidence of chondrogenic differentiation within cell aggregates only one of the twelve hMSC populations showed potential true potential to differentiate along this lineage. Previous evidence has shown that the potential for differentiation toward cell lineages is restricted by tissue from which hMSCs are derived[30, 31]. For our intended aim of improved integration of the graft/host interface following ACL reconstruction, poor chondrogenic and adipogenic differentiation of our isolated hMSCs is not a concern. However, a more standardised response to osteogenic stimuli between different hMSC populations will need to be optimised. We predict improved global differentiation when the amount of non-hMSC cells has been reduced from starting cultures though the greatest benefit will be achieved through modification of pro-osteogenic culture conditions with particular emphasis on the microenvironment presented by the scaffold.

5. Conclusions

We have demonstrated the feasibility of deriving hMSC populations from haemarthrotic fluid that has been aspirated in the acute clinical setting. Whilst clinical and scientific challenges remain we believe that these cells could fulfil a potential role in modulating the healing response to acute intra-articular injury.

ACKNOWLEDGEMENTS

This work was funded by The JGW Patterson Foundation and from a NESCIFellowship awarded to RAO. This work was supported by the UK NIHR Biomedical Research Centre for Ageing and Age-related disease award to the Newcastle upon Tyne Hospitals NHS Foundation Trust. We wish to also acknowledge technical support provided by the flow cytometry facility, Newcastle University.

REFERENCES

[3] Adesida AB, Grady LM, Khan WS, Hardingham TE. The matrix-forming phenotype of cultured human meniscus cells is enhanced after culture with fibroblast growth factor 2 and is further stimulated by hypoxia. Arthritis Res Ther 2006; 8: R61


[29] Jarocha D, Lukasiewicz E, Majka M. Advantages of mesenchymal stem cells (MSC) expansion directly from purified bone marrow CD105+ and CD271+ cells. Folia Histochem Cytobiol 2008; 46: 307-14
